Viabilidade da mensuração de marcadores de remodelação óssea em mulheres com lúpus eritematoso sistêmico

Bogaczewicz, Jarosław; Karczmarewicz, Elżbieta; Płudowski, Paweł; Ząbek, Jakub; Kowalski, Jan; Łukaszkiewicz, Jacek; Woźniacka, Anna

doi:10.1016/j.rbr.2014.10.004

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, clear strengths of our study include its design as an RCT and, as shown previously [9], the confirmation of an effective vitamin D treatment by a significant treatment effect on 25(OH)D and PTH levels and by its relatively large sample size when compared to previous studies on this topic. The validity of our results are emphasized by, in our observed cohort, the previously published well-known associations between markers of bone turnover [36], such as correlations between OC and CTX [37], or P1NP and OC [38]. Additionally, validity is substantiated by confirmation of well-known correlations of AP and bALP [39], OC and HbA1c [40,41], and OC and glucose [42].…”

Section: Discussionsupporting

confidence: 80%

Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011–2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI −0.029 to 0.056 µg/L; p = 0.533), CTX (MTE 0.024, 95% CI −0.163 to 0.210 ng/mL, p = 0.802), OC (MTE 0.020, 95% CI −0.062 to 0.103 ng/mL, p = 0.626), or P1NP (MTE −0.021, 95% CI −0.099 to 0.057 ng/mL, p = 0.597). Analyzing patients with 25(OH)D levels <50 nmol/L separately (n = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.

show abstract

Section: Discussionsupporting

confidence: 80%

Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

show abstract

Role of Secreted Frizzled-Related Protein 1 and Tumor Necrosis Factor-α (TNF-α) in Bone Loss of Patients with Rheumatoid Arthritis

Ginting

Hidayat

Sumariyono

et al. 2020

International Journal of Rheumatology

View full text Add to dashboard Cite

Bone loss is one of the emerging extra-articular manifestations of rheumatoid arthritis. TNF-α is the main inflammatory cytokine that can directly increase bone resorption. However, its role in bone formation is still unknown, especially related to secreted frizzled-related protein 1 (SFRP-1), an osteoblast inhibitor. This study examines the correlation between TNF-α and SFRP-1, with a bone turn over marker (CTX and P1NP). This is a cross-sectional study with 38 subjects of premenopausal female patients with RA. This study found that 60.6% of the patients were in remission or low disease activity. The median of TNF-α was 10.6 pg/mL, mean of SFRP-1 was 9.29 ng/mL, mean of CTX was 2.74 ng/mL, and the median of P1NP was 34.04 pg/ml. There is positive correlation between TNF-α and P1NP (r = 0:363, p = 0:026), also between SFRP-1 and P1NP (r = 0:341; p = 0:036). A low level of TNF-?, high level of SFRP-1, high level of CTX, and low level of P1NP in this study indicate a high bone turn over process, with dominant resorption activity in premenopausal female patients with RA.

show abstract

Bone turnover markers in relation to vitamin D status and disease activity in adults with systemic lupus erythematosus

Sarkissian

Sivaraman

Bout-Tabaku

et al. 2018

Lupus

View full text Add to dashboard Cite

Objective Patients with systemic lupus erythematosus (SLE) have altered bone metabolism and are at risk of osteoporosis. The aim of this study was to examine bone turnover markers in relation to vitamin D, disease activity, and clinical risk factors in patients with established SLE. Methods Clinical registry and biorepository data of 42 SLE patients were assessed. Serum samples were analyzed for osteocalcin as a marker of bone formation, C-terminal telopeptide of type 1 collagen (CTX) as a marker for bone resorption, and 25-hydroxy vitamin D. Results Patients with a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI) score of 3 or greater had a lower median osteocalcin level (P = 0.02) and lower 25-hydroxy vitamin D levels (P = 0.03) than those with a score of less than 3. No significant differences in bone turnover markers were observed between patients dichotomized into subgroups using a 25-hydroxy vitamin D cut-off of 30 ng/mL or by a daily prednisone dose greater than or 5 mg or less. Osteocalcin levels were negatively correlated with SLEDAI scores (P = 0.034), and were positively correlated with the CTX index (a ratio of measured CTX value to the upper limit of the normal value for age and gender) (P < 0.01). No association between the CTX index and SLEDAI scores was found. Conclusion SLE disease activity may have direct effects on bone formation, but no effects on bone resorption in this cohort of established SLE patients, probably related to the inflammation-suppressing effects of glucocorticoids, thereby inhibiting cytokine-induced osteoclast activity. A fine balance exists between disease control and the use of glucocorticoids with regard to bone health.

show abstract

Viabilidade da mensuração de marcadores de remodelação óssea em mulheres com lúpus eritematoso sistêmico

Cited by 5 publications

References 12 publications

Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial

Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial

Role of Secreted Frizzled-Related Protein 1 and Tumor Necrosis Factor-α (TNF-α) in Bone Loss of Patients with Rheumatoid Arthritis

Bone turnover markers in relation to vitamin D status and disease activity in adults with systemic lupus erythematosus

Contact Info

Product

Resources

About